Michael K. Wong

机构：Roswell Park Comprehensive Cancer Center · ORCID：0000-0001-7526-1262

发表论文 188 篇 · 总被引 7184 次 · h-index 40

代表论文

• RP1 Combined With Nivolumab in Advanced Anti–PD-1–Failed Melanoma (IGNYTE) (2025 · Journal of Clinical Oncology · 被引 41)
• OBX-115, an interleukin 2 (IL2)-sparing engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma. (2024 · Journal of Clinical Oncology · 被引 28)
• Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma (2025 · Journal of Clinical Oncology · 被引 15)
• Recommended guidelines for screening for underlying malignancy in extramammary Paget's disease based on anatomic subtype (2024 · Journal of the American Academy of Dermatology · 被引 12)
• LBA46 Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab (2024 · Annals of Oncology · 被引 9)
• Polyomavirus-positive Merkel cell carcinoma: the beginning of the beginning (2024 · Journal of Clinical Investigation · 被引 5)